Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

First line of the email MUST contain NCT # and Site #.


BMS Clinical Trials Contact Center www.BMSClinicalTrials.com 855-907-3286
Clinical.Trials@bms.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Back

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Recruiting

Open to: ALL

Age: 16.0 - N/A

London London London Metropolitan Borough of Wirral Liverpool Crownhill, Plymouth London

Medical Conditions

Lupus Erythematosus, Systemic
Lupus Nephritis

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jul 2025 May 2028

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Specified dose on specified days

Intervention Arm Group : Administration of CC-97540;

Intervention Type : DRUG
Intervention Description : Specified dose on specified days

Intervention Arm Group : Administration of CC-97540;

Intervention Type : DRUG
Intervention Description : Specified dose on specified days

Intervention Arm Group : Administration of CC-97540;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • King's College Hospital
    London
    London, City of
    SE5 9RL
  • Local Institution - 0061
    London
    London, City of
    NW1 2PG
  • Local Institution - 0057
    London
    London, City of
    W1T 7HA
  • Local Institution - 0090
    Metropolitan Borough of Wirral
    Merseyside
    L63 4JY
  • Local Institution - 0091
    Liverpool
    L9 7AL
  • Local Institution - 0102
    Crownhill, Plymouth
    PL6 8DH
  • University College London Hospital
    London
    London, City of
    NW1 2PG

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com 855-907-3286
Clinical.Trials@bms.com


First line of the email MUST contain NCT # and Site #.



The study is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT07015983
Last updated 16 March 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top